These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20217513)

  • 81. The effect of different volumes of high-intensity interval training on proinsulin in participants with the metabolic syndrome: a randomised trial.
    Ramos JS; Dalleck LC; Borrani F; Mallard AR; Clark B; Keating SE; Fassett RG; Coombes JS
    Diabetologia; 2016 Nov; 59(11):2308-2320. PubMed ID: 27480182
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The p21-activated kinase (PAK1) is involved in diet-induced beta cell mass expansion and survival in mice and human islets.
    Ahn M; Yoder SM; Wang Z; Oh E; Ramalingam L; Tunduguru R; Thurmond DC
    Diabetologia; 2016 Oct; 59(10):2145-55. PubMed ID: 27394663
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical characteristics and beta cell function in Chinese patients with newly diagnosed type 2 diabetes mellitus with different levels of serum triglyceride.
    Zheng S; Zhou H; Han T; Li Y; Zhang Y; Liu W; Hu Y
    BMC Endocr Disord; 2015 Apr; 15():21. PubMed ID: 25924608
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1).
    Puddu A; Sanguineti R; Montecucco F; Viviani GL
    Mediators Inflamm; 2013; 2013():975032. PubMed ID: 24307763
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Influence of islet function on typing and prognosis of new-onset diabetes after intensive insulin therapy.
    Fan H; Pan Q; Zhang P; Liu J; Xu Y; Yang X
    Med Sci Monit; 2013 Sep; 19():787-93. PubMed ID: 24056309
    [TBL] [Abstract][Full Text] [Related]  

  • 87. PAK1 limits the expression of the pro-apoptotic protein Bad in pancreatic islet β-cells.
    Wang Z; Thurmond DC
    FEBS Open Bio; 2012; 2():273-7. PubMed ID: 23650610
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
    Schernthaner G; Gross JL; Rosenstock J; Guarisco M; Fu M; Yee J; Kawaguchi M; Canovatchel W; Meininger G
    Diabetes Care; 2013 Sep; 36(9):2508-15. PubMed ID: 23564919
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Depletion of PAK1 enhances ubiquitin-mediated survivin degradation in pancreatic β-cells.
    Chen YC; Fueger PT; Wang Z
    Islets; 2013; 5(1):22-8. PubMed ID: 23514967
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effects of Extract from Solid-State Fermented Cordyceps sinensis on Type 2 Diabetes Mellitus.
    Kan WC; Wang HY; Chien CC; Li SL; Chen YC; Chang LH; Cheng CH; Tsai WC; Hwang JC; Su SB; Huang LH; Chuu JJ
    Evid Based Complement Alternat Med; 2012; 2012():743107. PubMed ID: 22474523
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.
    Zeng L; Lu H; Deng H; Mu P; Li X; Wang M
    Diabetes Technol Ther; 2012 Jan; 14(1):35-42. PubMed ID: 21877913
    [TBL] [Abstract][Full Text] [Related]  

  • 93. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinical approaches to preserve beta-cell function in diabetes.
    Wajchenberg BL
    Adv Exp Med Biol; 2010; 654():515-35. PubMed ID: 20217513
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.